EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.21
−0.32%Margins
Gross margin
49.4%
EBITDA margin
-3.1%
EBIT margin
-7.1%
Net margin
-23.0%
FCF margin
11.2%
-51.8%
Return on equity
-15.8%
Return on assets
-5.9%
Return on invested capital
0.63x
Asset turnover
$97.7M
Cash from operations
$2.72
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026